FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895491378> ?p ?o ?g. }

• W2895491378 endingPage "276" @default.
• W2895491378 startingPage "261" @default.
• W2895491378 abstract "Background/Aims: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically centered on paclitaxel-based chemotherapy. In this study, we aimed to evaluate whether miR-34a attenuates chemoresistance to paclitaxel by regulating target genes associated with drug resistance. Methods: We used data from The Cancer Genome Atlas to compare miR-34a expression levels in prostate cancer (PC) tissues with normal prostate tissues. The effects of miR-34a inhibition and overexpression on PC proliferation were evaluated in vitro via Cell Counting Kit-8 (CCK-8) proliferation, colony formation, apoptosis, and cell-cycle assays. A luciferase reporter assay was employed to identify the interactions between miR-34a and specific target genes. To determine the effects of up-regulation of miR-34a on tumor growth and chemo-resistance in vivo, we injected PC cells overexpressing miR-34a into nude mice subcutaneously and evaluated the rate of tumor growth during paclitaxel treatment. We examined changes in the expression levels of miR-34a target genes JAG1 and Notch1 and their downstream genes via miR-34a transfection by quantitative reverse transcription PCR (qRT-PCR) and western blot assay. Results: miR-34a served as an independent predictor of reduced patient survival. MiR-34a was down-regulated in PC-3PR cells compared with PC-3 cells. The CCK-8 assay showed that miR-34a overexpression resulted in increased sensitivity to paclitaxel while miR-34a down-regulation resulted in chemoresistance to paclitaxel in vitro. A study of gain and loss in a series of functional assays revealed that PC cells expressing miR-34a were chemosensitive. Furthermore, the overexpression of miR-34a increased the sensitivity of PC-3PR cells to chemotherapy in vivo. The luciferase reporter assay confirmed that JAG1 and Notch1 were directly targeted by miR-34a. Interestingly, western blot analysis and qRT-PCR confirmed that miR-34a inhibited the Notch1 signaling pathway. We found that miR-34a increased the chemosensitivity of PC-3PR cells by directly repressing the TCF1/ LEF1 axis. Conclusion: Our results showed that miR-34a is involved in the development of chemosensitivity to paclitaxel. By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage." @default.
• W2895491378 created "2018-10-12" @default.
• W2895491378 creator A5001756143 @default.
• W2895491378 creator A5003580350 @default.
• W2895491378 creator A5017445985 @default.
• W2895491378 creator A5017541508 @default.
• W2895491378 creator A5021459428 @default.
• W2895491378 creator A5024358037 @default.
• W2895491378 creator A5024385770 @default.
• W2895491378 creator A5033785543 @default.
• W2895491378 creator A5052835329 @default.
• W2895491378 creator A5058708429 @default.
• W2895491378 creator A5058780708 @default.
• W2895491378 creator A5064357077 @default.
• W2895491378 creator A5073309453 @default.
• W2895491378 creator A5080280424 @default.
• W2895491378 creator A5082314539 @default.
• W2895491378 creator A5090538195 @default.
• W2895491378 date "2018-01-01" @default.
• W2895491378 modified "2023-10-14" @default.
• W2895491378 title "MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis" @default.
• W2895491378 cites W1517911595 @default.
• W2895491378 cites W1540008871 @default.
• W2895491378 cites W1576913910 @default.
• W2895491378 cites W1744887380 @default.
• W2895491378 cites W1964962769 @default.
• W2895491378 cites W1996253589 @default.
• W2895491378 cites W2002995168 @default.
• W2895491378 cites W2013073866 @default.
• W2895491378 cites W2020170641 @default.
• W2895491378 cites W2021326683 @default.
• W2895491378 cites W2030197665 @default.
• W2895491378 cites W2037089056 @default.
• W2895491378 cites W2037467991 @default.
• W2895491378 cites W2059819216 @default.
• W2895491378 cites W2079113237 @default.
• W2895491378 cites W2080439368 @default.
• W2895491378 cites W2095904711 @default.
• W2895491378 cites W2122785662 @default.
• W2895491378 cites W2140021643 @default.
• W2895491378 cites W2145185329 @default.
• W2895491378 cites W2150417249 @default.
• W2895491378 cites W2156262690 @default.
• W2895491378 cites W2170685293 @default.
• W2895491378 cites W2171561444 @default.
• W2895491378 cites W2283845851 @default.
• W2895491378 cites W2333330203 @default.
• W2895491378 cites W2514003000 @default.
• W2895491378 cites W2556619639 @default.
• W2895491378 cites W2593926329 @default.
• W2895491378 cites W2746053356 @default.
• W2895491378 cites W2748687809 @default.
• W2895491378 cites W2749663845 @default.
• W2895491378 doi "https://doi.org/10.1159/000494004" @default.
• W2895491378 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282072" @default.
• W2895491378 hasPublicationYear "2018" @default.
• W2895491378 type Work @default.
• W2895491378 sameAs 2895491378 @default.
• W2895491378 citedByCount "38" @default.
• W2895491378 countsByYear W28954913782019 @default.
• W2895491378 countsByYear W28954913782020 @default.
• W2895491378 countsByYear W28954913782021 @default.
• W2895491378 countsByYear W28954913782022 @default.
• W2895491378 countsByYear W28954913782023 @default.
• W2895491378 crossrefType "journal-article" @default.
• W2895491378 hasAuthorship W2895491378A5001756143 @default.
• W2895491378 hasAuthorship W2895491378A5003580350 @default.
• W2895491378 hasAuthorship W2895491378A5017445985 @default.
• W2895491378 hasAuthorship W2895491378A5017541508 @default.
• W2895491378 hasAuthorship W2895491378A5021459428 @default.
• W2895491378 hasAuthorship W2895491378A5024358037 @default.
• W2895491378 hasAuthorship W2895491378A5024385770 @default.
• W2895491378 hasAuthorship W2895491378A5033785543 @default.
• W2895491378 hasAuthorship W2895491378A5052835329 @default.
• W2895491378 hasAuthorship W2895491378A5058708429 @default.
• W2895491378 hasAuthorship W2895491378A5058780708 @default.
• W2895491378 hasAuthorship W2895491378A5064357077 @default.
• W2895491378 hasAuthorship W2895491378A5073309453 @default.
• W2895491378 hasAuthorship W2895491378A5080280424 @default.
• W2895491378 hasAuthorship W2895491378A5082314539 @default.
• W2895491378 hasAuthorship W2895491378A5090538195 @default.
• W2895491378 hasBestOaLocation W28954913781 @default.
• W2895491378 hasConcept C104317684 @default.
• W2895491378 hasConcept C121608353 @default.
• W2895491378 hasConcept C126322002 @default.
• W2895491378 hasConcept C145059251 @default.
• W2895491378 hasConcept C150903083 @default.
• W2895491378 hasConcept C190283241 @default.
• W2895491378 hasConcept C207001950 @default.
• W2895491378 hasConcept C2777292972 @default.
• W2895491378 hasConcept C2780192828 @default.
• W2895491378 hasConcept C39845236 @default.
• W2895491378 hasConcept C502942594 @default.
• W2895491378 hasConcept C54009773 @default.
• W2895491378 hasConcept C54355233 @default.
• W2895491378 hasConcept C55493867 @default.
• W2895491378 hasConcept C555283112 @default.
• W2895491378 hasConcept C62112901 @default.

• next